Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma.

IF 0.4 Q4 OPHTHALMOLOGY

Open Ophthalmology Journal Pub Date : 2018-06-29 eCollection Date: 2018-01-01 DOI:10.2174/1874364101812010121

Kenji Inoue, Takeaki Ueda, Kyoko Ishida, Goji Tomita

{"title":"Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma.","authors":"Kenji Inoue, Takeaki Ueda, Kyoko Ishida, Goji Tomita","doi":"10.2174/1874364101812010121","DOIUrl":null,"url":null,"abstract":"Background: The Tafluprost/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited.Objective: To investigate the efficacy and safety of switching from tafluprost to TTFC in patients with Primary Open-Angle Glaucoma (POAG).Methods: Thirty-four eyes (34 patients) with POAG that did not achieve adequate IOP reduction on tafluprost were switched to TTFC with no washout period. IOP, systolic/diastolic blood pressure and pulse rate were measured 1 and 3 months later and compared with baseline values. All participants were asked about specific adverse reactions after 1 and 3 months of treatment. Patients also completed a questionnaire about preference and adherence after 1 month of treatment.Results: Mean IOP after 1 and 3 months was significantly lower than at baseline (14.2 ± 2.1 mmHg and 14.1 ± 2.3 mmHg, respectively, vs 16.0 ± 2.0 mmHg, P < 0.0001). Systolic/diastolic blood pressure and pulse rate were not significantly different from baseline after 1 and 3 months. The questionnaire indicated that the frequency of missing a dose was not different before (27.3%) or after (18.2%) switching to TTFC (P = 0.2371). There were five reports of adverse reactions (14.7%), including a corneal epithelium disorder, ocular irritation, skin irritation at the wrist, and chest pain. Two patients (5.9%) withdrew because of adverse reactions.Conclusion: Switching from tafluprost to TTFC achieved IOP control safely and was well accepted by patients.","PeriodicalId":46347,"journal":{"name":"Open Ophthalmology Journal","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047199/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Ophthalmology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874364101812010121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: The Tafluprost/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited.

Objective: To investigate the efficacy and safety of switching from tafluprost to TTFC in patients with Primary Open-Angle Glaucoma (POAG).

Methods: Thirty-four eyes (34 patients) with POAG that did not achieve adequate IOP reduction on tafluprost were switched to TTFC with no washout period. IOP, systolic/diastolic blood pressure and pulse rate were measured 1 and 3 months later and compared with baseline values. All participants were asked about specific adverse reactions after 1 and 3 months of treatment. Patients also completed a questionnaire about preference and adherence after 1 month of treatment.

Results: Mean IOP after 1 and 3 months was significantly lower than at baseline (14.2 ± 2.1 mmHg and 14.1 ± 2.3 mmHg, respectively, vs 16.0 ± 2.0 mmHg, P < 0.0001). Systolic/diastolic blood pressure and pulse rate were not significantly different from baseline after 1 and 3 months. The questionnaire indicated that the frequency of missing a dose was not different before (27.3%) or after (18.2%) switching to TTFC (P = 0.2371). There were five reports of adverse reactions (14.7%), including a corneal epithelium disorder, ocular irritation, skin irritation at the wrist, and chest pain. Two patients (5.9%) withdrew because of adverse reactions.

Conclusion: Switching from tafluprost to TTFC achieved IOP control safely and was well accepted by patients.

Abstract Image

查看原文本刊更多论文

原发性开角型青光眼患者从他氟前列素转换为他氟前列素/替莫洛尔固定联合治疗的疗效和安全性

背景:他氟前列素/替洛尔固定联合治疗(TTFC)降低眼压(IOP)的有效性和安全性已得到证实。然而，从他氟前列素到TTFC的直接比较是有限的。目的:探讨他氟前列素替代TTFC治疗原发性开角型青光眼(POAG)的疗效和安全性。方法:34例POAG患者(34例)在他氟前列素治疗下未能达到足够的IOP降低效果，将其切换到TTFC治疗，没有洗脱期。1个月和3个月后测量IOP、收缩压/舒张压和脉搏率，并与基线值进行比较。所有参与者在治疗1个月和3个月后被问及具体的不良反应。患者还在治疗1个月后完成了一份关于偏好和依从性的问卷调查。结果:1个月和3个月后的平均IOP显著低于基线(分别为14.2±2.1 mmHg和14.1±2.3 mmHg, vs 16.0±2.0 mmHg, P < 0.0001)。1个月和3个月后，收缩压/舒张压和脉搏率与基线无显著差异。问卷调查显示，切换到TTFC前(27.3%)和切换到TTFC后(18.2%)漏服一次剂量的频率没有差异(P = 0.2371)。有5例不良反应报告(14.7%)，包括角膜上皮病变、眼部刺激、手腕皮肤刺激和胸痛。2例(5.9%)因不良反应退出治疗。结论:从他氟前列素转换为TTFC可安全控制IOP，并为患者所接受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Ophthalmology Journal OPHTHALMOLOGY-

CiteScore

0.50

自引率

0.00%

发文量

期刊介绍： The Open Ophthalmology Journal is an Open Access online journal, which publishes research articles, reviews/mini-reviews, letters and guest edited single topic issues in all important areas of experimental and clinical research in ophthalmology, including use of ophthalmological therapies, devices and surgical techniques. The Open Ophthalmology Journal, a peer-reviewed journal, is an important and reliable source of current information on developments in the field. The emphasis will be on publishing quality papers rapidly and making them freely available to researchers worldwide.